This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): J-HER
CEL-SCI is developing a panel of drugs based on their proprietary L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology which are designed to mimic cell--cell interactions that stimulate the immune system. L.E.A.P.S. drugs are essentially a disease associated antigen fused with a T-cell binding ligand to stimulate T cells to drive an antigen-specific immune response. The antigenic L.E.A.P.S. constructs can be designed to preferentially elicit either a primarily (cellular) Th1 response or a humoral (antibody mediated) Th2 type response.
J-HER links the J-ICBL (immune cell binding ligand) peptide to a minimal antigenic peptide (epitope) from the HER-2/neu protein, a protein present in most human breast tumor cells.
Additional information available to subscribers only: